10.19

5.82% -0.63

Pre-market: 9.99 -0.20 -1.96%

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $10.19, with a volume of 2.28M. It is down -5.82% in the last 24 hours and up +14.11% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Previous Close:

$10.82

Open:

$10.7

24h Volume:

2.28M

Relative Volume:

0.99

Market Cap:

$1.53B

Revenue:

Net Income/Loss:

$-738.82M

P/E Ratio:

-1.464

EPS:

-6.9602

Net Cash Flow:

$-610.15M

1W Performance:

-2.39%

1M Performance:

+14.11%

6M Performance:

-42.53%

1Y Performance:

-50.41%

1-Day Range:

$10.03

$10.80

1-Week Range:

$9.945

$11.06

52-Week Range:

$7.48

$24.06

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1113)

Industry

Biotechnology (624)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

274

Twitter

@biohavenpharma

Next Earnings Date

2026-05-11

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	10.19	1.53B	0	-738.82M	-610.15M	-6.9602
VRTX Vertex Pharmaceuticals Inc	436.59	111.05B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	747.36	79.01B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	805.38	50.08B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	308.43	41.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.31	34.67B	5.36B	287.73M	924.18M	2.5229

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Canaccord Genuity	Buy
Feb-06-26	Initiated	Goldman	Buy
Jan-21-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-26-25	Downgrade	UBS	Buy → Neutral
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral
Sep-17-25	Initiated	Citigroup	Buy
Sep-03-25	Initiated	Raymond James	Strong Buy
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

01:34 AM

Spinocerebellar Ataxias Pipeline Advances Toward - openPR.com

01:34 AM

Apr 20, 2026

Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN

Apr 20, 2026

Apr 19, 2026

Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating - Insider Monkey

Apr 19, 2026

Responsive Playbooks and the BHVN Inflection - Stock Traders Daily

Apr 19, 2026

Apr 18, 2026

Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN

Apr 18, 2026

BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN

Apr 18, 2026

Biohaven (NYSE:BHVN) Upgraded by Wall Street Zen to Sell Rating - MarketBeat

Apr 18, 2026

Apr 17, 2026

Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects - Sahm

Apr 17, 2026

Apr 16, 2026

Biohaven Receives 'Moderate Buy' Rating from Analysts - National Today

Apr 16, 2026

Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 16, 2026

Apr 15, 2026

Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha

Apr 15, 2026

Biohaven reports details on discovery of BHV-2100 - BioWorld News

Apr 15, 2026

Apr 13, 2026

Why Institutions Are Turning Bullish on Biohaven—and the Catalyst That Could Unlock Its Value - NAI500

Apr 13, 2026

Why Biohaven Stock Crushed it on Monday - Yahoo Finance

Apr 13, 2026

FOMO Trade: What is the implied volatility of Biohaven LtdMarket Performance Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn

Apr 13, 2026

Biohaven (NYSE:BHVN) Stock Price Up 10.2%What's Next? - MarketBeat

Apr 13, 2026

CCORF Initiates Biohaven(BHVN.US) With Buy Rating, Announces Target Price $21 - Moomoo

Apr 13, 2026

Biohaven (NYSE:BHVN) Now Covered by Canaccord Genuity Group - MarketBeat

Apr 13, 2026

Biohaven’s BHV-1450 shows promise for pemphigus vulgaris - BioWorld News

Apr 13, 2026

Hedge Fund Bets: How does Biohaven Ltd score in quality rankings2026 Big Picture & Safe Capital Allocation Plans - baoquankhu1.vn

Apr 13, 2026

Whale Trades: How does Biohaven Ltd score in quality rankingsWeekly Risk Summary & High Yield Stock Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying - Insider Monkey

Apr 12, 2026

8 Healthcare Stocks Insiders Are Buying - Insider Monkey

Apr 12, 2026

Apr 11, 2026

Decliners Report: Is Biohaven Ltd showing insider buyingMarket Movers & Consistent Income Trade Recommendations - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Entry Recap: Is Biohaven Ltd showing insider buyingMarket Volume Report & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN - MarketBeat

Apr 09, 2026

Apr 08, 2026

Earnings Update: What is the long term forecast for Biohaven Ltd stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn

Apr 08, 2026

Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

BHVN PE Ratio & Valuation, Is BHVN Overvalued - Intellectia AI

Apr 04, 2026

BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart

Apr 03, 2026

Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm

Apr 03, 2026

Apr 02, 2026